Drug Trial Radar · NCT06242691
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Feb 28, 2024
Primary completion
Jun 17, 2025
Study completion Jun 17, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses
Conditions
- Advanced Solid Tumors
Interventions
MK-1200Biological
IV Infusion
AntiemeticDrug
One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs) - Part 1Time frame: During the first two 14-day cycles (Up to approximately 28 days)
- Number of Participants Who Experience One or More Adverse Events (AEs) - Part 1 & Part 2Time frame: Up to approximately 12 months
- Number of Participants Who Discontinue Study Intervention Due to an AE - Part 1 & Part 2Time frame: Up to approximately 9 months
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
The University of Louisville, James Graham Brown Cancer Center ( Site 0004)
Louisville, Kentucky
START Midwest ( Site 0014)
Grand Rapids, Michigan
South Texas Accelerated Research Therapeutics (START) ( Site 0005)
San Antonio, Texas
START Mountain Region ( Site 0015)
West Valley City, Utah
University of Virginia Health System-Hematology-Oncology ( Site 0009)
Charlottesville, Virginia
The Alfred Hospital ( Site 0103)
Melbourne, Victoria, Australia
Bradfordhill-Clinical Area ( Site 0301)
Santiago, Region M. de Santiago, Chile
Beijing Cancer hospital-Digestive Oncology ( Site 0401)
Beijing, Beijing Municipality, China
Fujian Cancer Hospital-oncology department ( Site 0409)
Fuzhou, Fujian, China
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)
Huai'an, Jiangsu, China
Rambam Health Care Campus-Oncology Division ( Site 0602)
Haifa, Israel
Hadassah Medical Center ( Site 0604)
Jerusalem, Israel
Rabin Medical Center-Oncology ( Site 0603)
Petah Tikva, Israel
Sheba Medical Center ( Site 0605)
Ramat Gan, Israel
Sourasky Medical Center ( Site 0601)
Tel Aviv, Israel
Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.